Our Blog Melanoma360

Featured image for “Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma”
09/30/2022

Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma

(Source:Georgetown University Medical Center) Originally published Sep 27, 2022, Medical Life Sciences Giving immunotherapy before targeted therapy improves survival in…
Blog - Melanoma360
Breaking News
Featured image for “Val Guild Honored at 2022 ASCO Annual Conference”
09/29/2022

Val Guild Honored at 2022 ASCO Annual Conference

by Alicia Rowell, Vice President Saturday, June 4 was a special evening. In Chicago that week many of the nation’s…
Blog - Melanoma360
Uncategorized
Featured image for “President’s Letter | September 2022”
09/27/2022

President’s Letter | September 2022

From the Desk of Samantha Guild Leaves are falling, pumpkins are out, football is on TV, and the kids are…
Blog - Melanoma360
President's Letter
Featured image for “AIM Welcomes Ann Garst Taylor as New Director of Community Engagement”
09/27/2022

AIM Welcomes Ann Garst Taylor as New Director of Community Engagement

By Mara Klecker Ann Garst Taylor, AIM at Melanoma’s new Director of Community Engagement, has nearly 30 years of volunteer…
Blog - Melanoma360
Uncategorized
Featured image for “AIM Welcomes Michelle Bessett as New Director of National Walks & Events”
09/27/2022

AIM Welcomes Michelle Bessett as New Director of National Walks & Events

by Mara Klecker Michelle Bessett has always loved working with and helping other people. As AIM at Melanoma’s new Director…
Blog - Melanoma360
Uncategorized
Featured image for “Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%”
09/16/2022

Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%

(NEWS PROVIDED BY  Bristol Myers Squibb, September 16, 2022, ) Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the…
Blog - Melanoma360
Breaking News
Featured image for “Spirituality and Cancer Care With Michael Eselun, BCC”
09/13/2022

Spirituality and Cancer Care With Michael Eselun, BCC

 When faced with a cancer diagnosis, some patients rely on their spirituality to cope and find meaning behind the…
Blog - Melanoma360
Podcast
Featured image for “ESMO: TIL therapy improves on Yervoy in melanoma trial”
09/13/2022

ESMO: TIL therapy improves on Yervoy in melanoma trial

(NEWS PROVIDED BY  Pharmaphorum, September 11, 2022, Phil Taylor) A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has…
Blog - Melanoma360
Breaking News
Featured image for “Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors”
09/12/2022

Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors

(NEWS PROVIDED BY Regeneron Pharmaceuticals, Inc. Sep 12, 2022, 02:30 ET) Positive clinical data presented in a mini-oral session at ESMO…
Blog - Melanoma360
Breaking News
Featured image for “Pembrolizumab in the Neoadjuvant Setting Benefits EFS in High-Risk Melanoma”
09/11/2022

Pembrolizumab in the Neoadjuvant Setting Benefits EFS in High-Risk Melanoma

Neoadjuvant IO Boosts High-Risk Melanoma EFS Results from the phase 2 SWOG S1801 study show that for patients given pembrolizumab…
Blog - Melanoma360
Breaking News
09/30/2022

Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma

(Source:Georgetown University Medical Center) Originally published Sep 27, 2022, Medical Life Sciences Giving immunotherapy before targeted therapy improves survival in…
Featured image for “Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma”
Blog - Melanoma360
 | 
Breaking News
09/29/2022

Val Guild Honored at 2022 ASCO Annual Conference

by Alicia Rowell, Vice President Saturday, June 4 was a special evening. In Chicago that week many of the nation’s…
Featured image for “Val Guild Honored at 2022 ASCO Annual Conference”
Blog - Melanoma360
 | 
Uncategorized
09/27/2022

President’s Letter | September 2022

From the Desk of Samantha Guild Leaves are falling, pumpkins are out, football is on TV, and the kids are…
Featured image for “President’s Letter | September 2022”
Blog - Melanoma360
 | 
President's Letter
09/27/2022

AIM Welcomes Ann Garst Taylor as New Director of Community Engagement

By Mara Klecker Ann Garst Taylor, AIM at Melanoma’s new Director of Community Engagement, has nearly 30 years of volunteer…
Featured image for “AIM Welcomes Ann Garst Taylor as New Director of Community Engagement”
Blog - Melanoma360
 | 
Uncategorized
09/27/2022

AIM Welcomes Michelle Bessett as New Director of National Walks & Events

by Mara Klecker Michelle Bessett has always loved working with and helping other people. As AIM at Melanoma’s new Director…
Featured image for “AIM Welcomes Michelle Bessett as New Director of National Walks & Events”
Blog - Melanoma360
 | 
Uncategorized
09/16/2022

Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%

(NEWS PROVIDED BY  Bristol Myers Squibb, September 16, 2022, ) Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the…
Featured image for “Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%”
Blog - Melanoma360
 | 
Breaking News
09/13/2022

Spirituality and Cancer Care With Michael Eselun, BCC

 When faced with a cancer diagnosis, some patients rely on their spirituality to cope and find meaning behind the…
Featured image for “Spirituality and Cancer Care With Michael Eselun, BCC”
Blog - Melanoma360
 | 
Podcast
09/13/2022

ESMO: TIL therapy improves on Yervoy in melanoma trial

(NEWS PROVIDED BY  Pharmaphorum, September 11, 2022, Phil Taylor) A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has…
Featured image for “ESMO: TIL therapy improves on Yervoy in melanoma trial”
Blog - Melanoma360
 | 
Breaking News
09/12/2022

Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors

(NEWS PROVIDED BY Regeneron Pharmaceuticals, Inc. Sep 12, 2022, 02:30 ET) Positive clinical data presented in a mini-oral session at ESMO…
Featured image for “Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors”
Blog - Melanoma360
 | 
Breaking News
09/11/2022

Pembrolizumab in the Neoadjuvant Setting Benefits EFS in High-Risk Melanoma

Neoadjuvant IO Boosts High-Risk Melanoma EFS Results from the phase 2 SWOG S1801 study show that for patients given pembrolizumab…
Featured image for “Pembrolizumab in the Neoadjuvant Setting Benefits EFS in High-Risk Melanoma”
Blog - Melanoma360
 | 
Breaking News